Key result
Patients with mixed hyperlipidemia and isolated hypercholesterolemia had significantly lower total IGF-I levels compared to healthy controls (153±54 ng/ml and 164±60 ng/ml vs 209±73 ng/ml, respectively).
Cross-Sectional (n=118)
No
Patients with mixed hyperlipidemia and isolated hypercholesterolemia have reduced total IGF-I levels compared to healthy controls, suggesting an independent trait of metabolic syndrome that may play a role in atherogenesis.
Lower IGF-I in hyperlipidemia is hypothesis-generating; leaves open its causal role in atherogenesis or therapeutic targeting.
Previous studies revealed altered levels of the circulating insulin-like growth factor-I (IGF-I) and of its binding protein-3 (IGFBP-3) in subjects with coronary atherosclerosis, metabolic syndrome and premature atherosclerosis. Hyperlipidemia is a powerful risk factor of atherosclerosis. We expected IGF-I and IGFBP-3 alterations in subjects with moderate/severe hyperlipidemia but without any clinical manifestation of atherosclerosis. Total IGF-I and IGFBP-3 were assessed in 56 patients with mixed hyperlipidemia (MHL; cholesterol >6.0 mmol/l, triglycerides >2.0 mmol/l), in 33 patients with isolated hypercholesterolemia (IHC; cholesterol >6.0 mmol/l, triglycerides <2.0 mmol/l), and in 29 healthy controls (cholesterol<6.0 mmol/l, triglycerides<2.0 mmol/l). The molar ratio of IGF-I/IGFBP-3 was used as a measure of free IGF-I. IHC subjects differed from controls by lower total IGF-I (164+/-60 vs. 209+/-73 ng/ml, p=0.01) and IGF-I /IGFBP-3 ratio (0.14+/-0.05 vs. 0.17+/-0.04, p=0.04). Compared to controls, MHL subjects had lower total IGF-I (153+/-54 ng/ml, p=0.0002) and IGFBP-3 (2.8+/-0.6 mg/ml, p<0.0001), but higher IGF-I/IGFBP-3 ratio (0.25+/-0.06, p<0.0001). Differences remained significant after the adjustment for clinical and biochemical covariates, except for triglycerides. Patients with both IHC and MHL have lower total IGF-I compared to controls. The mechanism is presumably different in IHC and MHL. Because of prominent reduction of IGFBP-3 in patients with MHL, they have reduced total IGF-I despite the actual elevation IGF-I/IGFBP-3 ratio as a surrogate of free IGF-I.
No takes yet. Share an insight, caveat, or question.
Malík et al. (2008) conducted a cross-sectional in Hyperlipidemia (n=118). Hyperlipidemia (Mixed hyperlipidemia and isolated hypercholesterolemia) vs. Normolipidemic healthy controls was evaluated on Total IGF-I levels (p=0.0002). Patients with mixed hyperlipidemia and isolated hypercholesterolemia had significantly lower total IGF-I levels compared to healthy controls (153±54 ng/ml and 164±60 ng/ml vs 209±73 ng/ml, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: